We are live on
!
Find out more
SGA
Sector Gamma AS Portfolio holdings
AUM
$423M
1-Year Est. Return
17.56%
This Fund
S&P 500
This Quarter
Est. Return
+7.68%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$403M
AUM Growth
+$97.4M
(+32%)
Cap. Flow
+$82.6M
Cap. Flow
% of AUM
20.49%
Top 10 Holdings %
Top 10 Hldgs %
53.32%
Holding
44
New
6
Increased
29
Reduced
6
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$9.93M |
| 2 |
Pfizer
PFE
|
+$8.2M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$8.19M |
| 4 |
Medtronic
MDT
|
+$7.3M |
| 5 |
Viatris
VTRS
|
+$6.51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qiagen
QGEN
|
+$5.62M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$3.28M |
| 3 |
TG Therapeutics
TGTX
|
+$2.95M |
| 4 |
Elevance Health
ELV
|
+$2.85M |
| 5 |
Tenet Healthcare
THC
|
+$2.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Avantor
AVTR
$7.28B
| $5.95M | 1.48% |
477,104
+104,466
| +28% | +$1.35M |
|
27
Organon & Co
OGN
$3.54B
| $5.81M | 1.44% |
+543,711
| New | +$5.34M |
|
28
Edwards Lifesciences
EW
$48.9B
| $5.68M | 1.41% |
72,980
+30,980
| +74% | +$2.42M |
|
29
DexCom
DXCM
$29.2B
| $5.17M | 1.28% |
76,821
+26,821
| +54% | +$2.12M |
|
30
Ascendis Pharma A/S
ASND
$16.5B
| $4.84M | 1.2% |
24,327
+7,327
| +43% | +$1.37M |
|
31
HCA Healthcare
HCA
$82.2B
| $4.64M | 1.15% |
10,883
+2,883
| +36% | +$1.12M |
|
32
Icon
ICLR
$12.8B
| $4.37M | 1.08% |
+24,967
| New | +$4.18M |
|
33
Solventum
SOLV
$13.7B
| $4.33M | 1.07% |
59,259
+21,259
| +56% | +$1.56M |
|
34
Kura Oncology
KURA
$948M
| $3.88M | 0.96% |
+438,415
| New | +$3.13M |
|
35
Lantheus
LNTH
$6.8B
| $3.3M | 0.82% |
64,403
+14,102
| +28% | +$881K |
|
36
Tandem Diabetes Care
TNDM
$1.24B
| $3.27M | 0.81% |
269,542
+59,019
| +28% | +$799K |
|
37
Syndax Pharmaceuticals
SNDX
$1.98B
| $3.24M | 0.8% |
+210,814
| New | +$2.76M |
|
|
38
Elevance Health
ELV
$82.9B
| $3.1M | 0.77% |
9,603
-9,176
| -49% | -$2.85M |
|
39
Certara
CERT
$1.08B
| $2.82M | 0.7% |
+230,565
| New | +$2.52M |
|
40
BioNTech
BNTX
$23.3B
| $2.73M | 0.68% |
27,732
-9,738
| -26% | -$1.04M |
|
|
ACLX
41
DELISTED
Arcellx
ACLX
| $2.63M | 0.65% |
32,009
+7,009
| +28% | +$505K |
|
|
42
Qiagen
QGEN
$8.35B
| – | – |
-117,000
| Closed | -$5.62M |
|
|
43
TG Therapeutics
TGTX
$8.26B
| – | – |
-82,000
| Closed | -$2.95M |
|
|
44
Tenet Healthcare
THC
$16.7B
| – | – |
-12,500
| Closed | -$2.2M |
|
Similar funds
AFWM
MP
DS
RS
DF
OGM
CPIM
MPPLM
Sector Gamma AS's Q3 2025 Portfolio in Review
As of Q3 2025, Sector Gamma AS held 44 positions worth $403M, up 32% from $306M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Sector Gamma AS deployed $82.6M of net new capital in Q3 2025, opening 6 new positions and adding to 29 existing holdings. Its largest new stake was Viatris: 668,851 shares worth $6.62M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $3.28M trimmed.
- Sector Gamma AS's largest Q3 2025 buy was Viatris: 668,851 shares worth $6.62M.
- Sector Gamma AS added most to Merck in Q3 2025, an estimated $9.93M increase.
- Sector Gamma AS's biggest Q3 2025 reduction was Thermo Fisher Scientific, cutting an estimated $3.28M.
- Sector Gamma AS fully exited Qiagen in Q3 2025, selling an estimated $5.62M.
- Sector Gamma AS's ten largest holdings make up 53% of its $403M portfolio in Q3 2025.
- Sector Gamma AS opened 6 new positions and closed 3 in Q3 2025.
- Sector Gamma AS's portfolio value rose 32% quarter-over-quarter to $403M.
Based on Sector Gamma AS's 13F filing for Q3 2025, filed 31 Oct 2025.